Research at the 2013 Genitourinary Cancers Symposium

Posted By News On February 13, 2013 - 4:30pm

The 2013 Genitourinary Cancers Symposium has announced research to be presented at this year's meeting. Three of the featured studies focus on the prevention, diagnosis and treatment of prostate cancers; another study looks at a new immunotherapy for metastatic kidney cancer.

Long-term survival of subjects in a prostate cancer prevention trial. General Poster Session A, Thursday, February 14, 2013, 11:45 AM – 01:15 PM EST, Thursday, February 14, 2013, 05:05 PM – 06:35 PM EST, Rosen, Gatlin Ballroom B, Phyllis J. Goodman, M.S.

"A randomized trial designed to evaluate finasteride as a chemopreventative agent in prostate cancer has been previously reported (NEJM 349:213-222, 2003) and demonstrated an almost 25% reduction in the risk of being diagnosed with prostate cancer over a 7-year period for those receiving finasteride as opposed to placebo; and an increased risk of higher Gleason grade tumors in those receiving finasteride, although it was unclear whether this latter finding represented a true change in the biology of the tumors in response to finasteride, or an artificial by-product on the way the trial was conducted.

If finasteride truly affected the natural history of the cancer, then this should be reflected as a long-term reduction of survival in this group. In this report, with follow-up to 18 years, 7-year administration of finasteride does not decrease overall mortality from prostate cancer despite the diagnosis of higher grade tumors, but significantly reduces the risk of a prostate cancer diagnosis."

Validation of the biopsy-based genomic prostate score (GPS) as a predictor of high-grade or extracapsular prostate cancer to improve patient selection for active surveillance (AS).

Thursday, February 14, 2013, 05:05 PM – 06:35 PM EST, Rosen, Gatlin Ballroom B,

Matthew R. Cooperberg, MD, MPH, University of California, San Francisco

"PSA based screening for prostate cancer has resulted in the increased diagnosis of many cases of clinically insignificant prostate cancer that will never harm a man in his lifetime.

This has popularized the concept of active surveillance where patients are monitored rather than definitively treated for their localized prostate cancer.

The development of this genomic prostate score (GPS) provides a unique new tool with more information than is currently routinely available to allow physicians and their patients to choose the prostate cancer active surveillance approach with confidence."

The effect of therapeutic anticoagulation on overall survival (OS) in men receiving docetaxel chemotherapy for metastatic castration-resistant prostate cancer (mCRPC).

Thursday, February 14, 2013, 11:45 AM – 01:15 PM EST, Thursday, February 14, 2013, 05:05 PM – 06:35 PM EST, Rosen, Gatlin Ballroom B, Caroline F. Pratz, CRNP, Johns Hopkins Sidney Kimmel - Comprehensive Cancer Center

Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC)

Saturday, February 16, 2013, 06:45 AM – 07:55 AM EST, Saturday, February 16, 2013, 11:50 AM – 01:05 PM EST, Rosen, Gatlin Ballroom B, Asim Amin, MD, PhD, Carolinas Medical Center, Blumental Cancer Center

"Advanced metastatic kidney cancer carries a poor prognosis with newer oral medications and immunotherapy each showing some modest improvements in survival.

This study uses a patient's own specific cancer fighting immune cells (AGS-003) in combination with a standard oral medication, sunitinib, known as a targeted therapy that blocks kidney cancer's specific pathways that contribute to cancer growth and survival.

This novel combination therapy using patient specific immunotherapy combined with an oral agent showed significant benefits with a doubling of survival in patients with aggressive metastatic kidney cancer. This is very encouraging and will need to be confirmed in a larger number of patients."

Post new comment

The content of this field is kept private and will not be shown publicly.
  • Allowed HTML tags: <a> <em> <img> <strong> <object> <cite><p><br><i><b><center><ul><li><div><html5:figure><html5:figcaption>
  • Lines and paragraphs break automatically.

More information about formatting options

CAPTCHA
Sorry, we know you're not a spambot, but they're out there